HelpLine 1-800-298-2436

New Option for Patients with ALK Mutations

Friday, May 26, 2017Today the Food and Drug Administration (FDA) approved using Zykadia (ceritinib) first line for ALK positive patients. The drug has already been approved for patients taking Xalkori (crizotinib) who experienced a reoccurrence. For more details, click here.